此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Safety, Efficacy and Preventative Effect of a Head Lice Product (X92001483) vs. Nix Creme Rinse (1% Permethrin).

2026年6月16日 更新者:Oystershell NV

In Vivo Testing : A Two-Arm, Randomized, Controlled, Investigator/Assessor-Blinded, Comparative Study to Evaluate the Safety, Efficacy, and Preventative Effect of a Head Lice Physically Acting Product: 2 in 1 SHAMPOO EU VERSION (X92001483) vs NIX CREME RINSE (1% Permethrin) in Subjects With Head Lice.

To compare the safety, effectiveness, and preventive benefits of a medical device (X92001483) against Nix Cream Rinse (1% Permethrin) in people with head lice

研究概览

地位

招聘中

详细说明

Compare Safety, Efficacy and preventative effect of a medical device with a physical mode of action against Nix Cream Rinse (1% Permethrin) in Subjects with Head Lice in a two-arm, randomized, controlled, Investigator/Assessor-blinded comparative study.

研究类型

介入性

注册 (估计的)

98

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Florida
      • Maitland、Florida、美国、32751
        • 招聘中
        • LSRN

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 孩子
  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  1. Gender: male / female.
  2. The subject or his/her parent/legal guardian (from age 12-17) must give written informed consent (after having been informed orally and by written text about the benefits and potential risks of the trial, as well as information regarding the insurance, taken out to cover the subjects participating in the study). A caregiver must sign an informed consent agreement for children not old enough to do so. Children aged 6-11 years of age will be administered a child's assent form. The subject or his/her parent/legal guardian must be capable of understanding and providing written informed consent.
  3. Age ≥ 1 year of age at the time of enrollment.
  4. Subject agree to not use any other anti-lice or preventative treatment or medicated hair grooming products for the duration of the study (through last visit day- Day 14).
  5. Subject must have an active head lice infestation defined as at least 5 live lice (adults and/or nymphs) and 5 live nits based on magnified observations, present on the scalp and/or hair, as determined by a trained evaluator.
  6. The subject is in good general health based on medical history.
  7. Female subjects of childbearing potential must have a negative pregnancy test at screening and agree to use a reliable method of birth control (as described in section 7.8) during duration of the study.
  8. The parent or legal guardian of a child subject must consent to the screening of other household members for head lice. If additional household members are found to have head lice and meet eligibility criteria, they must be enrolled in the study for all household members to qualify for participation.
  9. Have a single place of residence or agree to remain at the current residence for the duration of the study.
  10. Subject agrees not to additionally shampoo, wash, or rinse their hair or scalp for 24-hours post treatment.
  11. The subject agrees not to cut or chemically treat their hair while participating in the study.
  12. Subject agrees to follow all study instructions, including attending all follow-up appointments.

Exclusion Criteria:

  1. Application of any form of head lice treatment, whether prescription or over-the counter (OTC), or home remedy for 14 days prior to their screening visit (Visit 1).
  2. Application of any topical medication of any kind on the hair or scalp for a period of 48 hours prior to the screening visit.
  3. Use of systemic or topical drugs or medications, including systemic antibiotics, which in the opinion of the investigative personnel may interfere with the study results.
  4. Known skin allergies, multiple drug allergies or multiple allergies to cosmetic products.
  5. History of allergy or hypersensitivity to active ingredients, or constituents of the investigational or comparator products.
  6. Subject with any visible skin/scalp condition at the treatment site which, in the opinion of the investigative personnel, will interfere with the evaluation of the investigational product.
  7. Subjects with chronic scalp disorder.
  8. Subject or his/her legal guardian who, in the opinion of the investigative personnel, do not understand the subject requirements for study participations and/or may be likely to exhibit poor compliance with the required visits.
  9. Females who are pregnant or nursing.
  10. Hair longer than waist length.
  11. Subject suspected or known not to follow instructions
  12. Previous participation in this study or participation in any other investigational trial within the preceding 14 days.
  13. The subject is directly affiliated to the investigator site personnel and/or their immediate families. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted.
  14. The subject is an Oystershell employee or is an employee of a third-party organization involved in the study.
  15. People with dreadlocks or clips in hair that cannot be removed or a person who does not want to remove these.
  16. Hair that is too difficult to work with as assessed by the study staff.
  17. Families excluded where lice exist however a family member decline enrollment in the study.
  18. Subjects who are receiving, or are expected to receive, any antibiotic therapy during the study period will be excluded.
  19. No more than one working male subject per household may be excluded from evaluation if determined to be lice free by self-report or caregiver observation.
  20. All household members of the subject, other than excluded male adult, must be screened for head lice by a certified head lice professional. If additional household members are found to have head lice and meet the study criteria, they will be referred to LSRN Research and enrolled in study. If a household member declines enrollment, all family members will be excluded from the study.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:Medical Device X92001483
Treatment of subjects with head Lice with the standard of care product Nix Creme Rinse on day 0 and day 7, followed by intermediate application of the medical device (X92001483) with a physical mode of action applied every 3 days.
Treatment of subjects with Head Lice with a medical device (X92001483) with a physical mode of action on day 0, day 7, day 10, day 13 and day 14.
无干预:Nix Cream Rinse (1% Permethrin)
Treatment of subjects with Head Lice with Nix Cream Rinse (1% Permethrin) with a physical mode of action on day 0 and day 7.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Preventative Effect
大体时间:14 days
Determin whether subjects treated with the medical device X92001943 after treatment with Nix Creme Rinse maintain a higher cure rate at the end of the study compared with subjects treated only with Nix Creme Rinse.
14 days
Maintenance of cure rate over time
大体时间:day 3, day 7, day 10, day 13 and day 14
To assess the maintenance of cure over time: To compare cure rates between subjects treated with Nix Creme Rinse and the medical device X92001483 at interim visits in order to evaluate the presence and persistence of the preventive effect of the investigational product relative to standard of care product (Nix creme rinse) alone.
day 3, day 7, day 10, day 13 and day 14

次要结果测量

结果测量
措施说明
大体时间
Time to re-infestation
大体时间:14 days
Characterize the time to re-infestation in each treatment group
14 days
Number of live lice
大体时间:Day 0, day 3, day 7, day 10, days 13, day 14
To compare the number of live lice detected at each assessment across treatment groups.
Day 0, day 3, day 7, day 10, days 13, day 14
Local tolerability
大体时间:day 0, day 3, day 7, day 10, day 13 and day 14
To evaluate the local tolerability of the standard of care product and investigational product, as measured by subject reported symptoms (eg: burning, paraesthesia, pruritus) following application.
day 0, day 3, day 7, day 10, day 13 and day 14
Scalp and skin irritation
大体时间:day 0, day 3, day 4, day 7, day 10, day 13 and day 14
To evaluate scalp and skin irritation by study staff (secondary infection, erythema, excoriation) following product application.
day 0, day 3, day 4, day 7, day 10, day 13 and day 14
Adverse advents
大体时间:Day 0, day 3, day 7, day 10, day 13 and day 14
To record and characterize all treatment-emergent adverse events occurring during the study.
Day 0, day 3, day 7, day 10, day 13 and day 14

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

合作者

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年5月1日

初级完成 (估计的)

2026年9月1日

研究完成 (估计的)

2026年12月1日

研究注册日期

首次提交

2026年6月16日

首先提交符合 QC 标准的

2026年6月16日

首次发布 (实际的)

2026年6月22日

研究记录更新

最后更新发布 (实际的)

2026年6月22日

上次提交的符合 QC 标准的更新

2026年6月16日

最后验证

2026年6月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅